The stock has Return on Assets (ROA) of -23.9 percent.
Short traders are feeling a little more bearish on shares of the company lately as implied by the increase in short interest.
Among 9 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Citigroup Inc. began coverage on shares of Abeona Therapeutics in a report on Tuesday. Company shares last traded at $17.50 which is well above $14.23, the stock's 50 day moving average and much higher than the 200 day moving average of $8.38. The firm has "Buy" rating by Cantor Fitzgerald given on Thursday, September 8.
Insider Trades for Abeona Therapeutics Inc. show that the latest trade was made on 7 Nov 2016 where Ahn (Mark J), the Director completed a transaction type "Buy" in which 150000 shares were traded at a price of $2.31. On Friday, October 6 the stock rating was maintained by Cantor Fitzgerald with "Buy". The firm has "Buy" rating by Maxim Group given on Wednesday, December 16. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned "Buy" rating by Maxim Group on Thursday, September 29. FBR Capital maintained the stock with "Buy" rating in Thursday, May 25 report.
(CELG) Position Maintained by Cardinal Capital Management
Finally, Leerink Swann reaffirmed an outperform rating on shares of Celgene Corporation in a research note on Thursday, June 22nd. Campbell Newman Asset owns 11,766 shares or 0.1% of their U.S. portfolio. 1,196 were reported by Welch Gru Limited Liability Co.
10/9/2017-HC Wainwright Reiterated Rating of Buy. Citigroup maintained it with "Neutral" rating and $13 target in Wednesday, August 10 report. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned "Buy" rating by Jefferies on Friday, January 6. Next quarter's EPS is forecasted at $-0.17 with next year's EPS projected to be $-0.77. (NASDAQ:ABEO) by some 2,718,280 shares, 26 decreased positions by 1,639,601 and 20 held positions by 11,043,544. It has outperformed by 134.32% the S&P500. Advisors Lp, which now holds $29.48 million worth of this stock and that ownership represents almost 3.9% of its market capitalization. The Business's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -39.135309, and a current Price to Earnings ratio of -30.800124.
Analysts await AbbVie Inc (NYSE:ABBV) to report earnings on October, 27. NasdaqCM:ABEO is -0.032467. This is calculated by taking the earnings per share and dividing it by the last closing share price. GE's profit will be $4.30 billion for 11.80 P/E if the $0.50 EPS becomes a reality. After $1.42 actual EPS reported by AbbVie Inc for the previous quarter, Wall Street now forecasts -3.52% negative EPS growth. It turned negative, as 85 investors sold GE shares while 816 reduced holdings. 18 funds opened positions while 55 raised stakes. Moller Svcs has 37,915 shares. The company has Beta Value of 2.29 and ATR value of 1.46. Jennison Assocs Ltd Liability stated it has 0.08% in General Electric Company (NYSE:GE). Parkwood Llc has 135,000 shares for 0.27% of their portfolio. Axa reported 0.44% in General Electric Company (NYSE:GE). The stock grabbed 22 new institutional investments totaling 753,245 shares while 9 institutional investors sold out their entire positions totaling 852,383 shares. Wells Fargo Mn owns 149,671 shares or 0% of their USA portfolio. Argent Capital Mgmt Ltd Co holds 0.54% of its portfolio in General Electric Company (NYSE:GE) for 499,710 shares.
Since May 4, 2017, it had 0 buys, and 5 insider sales for $18.84 million activity.
- Shkodran Mustafi adds to Arsène Wenger's Arsenal woes
- Who was Aarushi Talwar?
- North Korean Foreign Minister: Pyongyang at 'state of equal power with US'
- Aerie Pharmaceuticals, Inc. (AERI) PT Set at $65.00 by Canaccord Genuity
- Jamie Carragher names Chelsea star as one of Premier League's best
- Himachal Pradesh Election Dates To Be Announced At 4 PM
- Amazon Kindle Oasis with 7-inch display, waterproof design launched in India
- Google to disable Home Mini top touch functionality after 24/7 recording issue
- No Colombia pact, insists Peru's Tapia
- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), Southwestern Energy Company (NYSE:SWN)